Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Current status of therapy with omalizumab in children.
[allergic bronchopulmonary aspergillosis]
There
are
a
considerable
number
of
patients
with
moderate
-
to
-
severe
uncontrolled
asthma
needing
additional
therapy
.
Omalizumab
,
an
anti-
IgE
monoclonal
antibody
,
improves
control
while
reducing
IgE-mediated
airway
inflammation
and
potentially
interfering
in
the
progressive
remodeling
process
.
The
clinical
implications
are
reductions
in
the
required
doses
of
inhaled
steroids
,
a
decrease
in
exacerbation
number
,
and
a
reduction
in
emergency
room
visits
and
hospitalizations
.
In
addition
to
its
use
in
asthma
,
there
is
an
increasing
interest
on
the
use
of
omalizumab
for
other
uncontrolled
IgE-mediated
diseases
,
supported
by
the
favorable
risk-benefit
background
.
The
present
review
explores
the
most
recent
publications
on
the
use
of
omalizumab
for
allergic
asthma
and
other
atopic
conditions
in
children
.
Omalizumab
has
also
shown
efficacy
in
allergic
rhinitis
,
and
it
is
being
investigated
in
the
treatment
of
anaphylaxis
,
food
allergy
,
atopic
dermatitis
,
and
chronic
spontaneous
urticaria
,
as
well
as
cystic
fibrosis
and
allergic
bronchopulmonary
aspergillosis
.
Despite
the
benefits
shown
so
far
,
more
data
are
needed
for
optimal
use
in
these
conditions
,
particularly
looking
at
the
safety
issues
that
have
to
be
confirmed
.
Confirmatory
evidence
on
the
efficacy
and
safety
of
omalizumab
in
children
is
reviewed
,
as
well
as
newest
fields
of
applicability
in
which
IgE
is
involved
in
disease
mechanism
.
Diseases
Validation
Diseases presenting
"and it is being investigated in the treatment of anaphylaxis"
symptom
allergic bronchopulmonary aspergillosis
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom